research Most Baricitinib Responders Achieved Full Scalp Hair Regrowth: Findings from Adult and Paediatric BRAVE-AA Trials
Baricitinib effectively regrows scalp hair in most people with severe alopecia areata.
Search
for
Sort by
Research
690-720 / 1000+ results 
research Oral tofacitinib for the treatment of alopecia areata in pediatric patients
Tofacitinib taken by mouth helps treat hair loss in children.
research Molecular pathways involved in hair follicle tumor formation: all about mammalian target of rapamycin?
mTOR may link different pathways in hair follicle tumor formation.
research 972 The ATP-dependent chromatin remodeler BRG1 controls epidermal keratinocytes migration during human cutaneous wound healing
BRG1 is essential for skin cells to move and heal wounds properly.
research LB789 Novel IFNγ aptamer TAGX-0003 protected hair follicles from immune privilege collapse and reversed Alopecia Areata like phenotype in humanized mouse model
TAGX-0003 protected hair follicles and reversed alopecia areata in a mouse model.
research Response of alopecia areata of the beard to oral tofacitinib
Oral tofacitinib is a promising treatment for beard hair loss in alopecia areata.
research N-(3,5-Dimethylphenyl)-3-Methoxybenzamide (A3B5) Targets TRP-2 and Inhibits Melanogenesis and Melanoma Growth
A3B5 can reduce skin pigmentation and slow melanoma growth.
research 5α-Reductase type 2 gene variant associations with prostate cancer risk, circulating hormone levels and androgenetic alopecia
A49T gene variant linked to higher prostate cancer risk, lower hormone levels, and slightly reduced balding risk.
research The Role of 5αR Inhibitors in the Early Growth of Pca Cells
5αR inhibitors help slow early prostate cancer cell growth, suggesting combined treatments are needed.
research ISID1338 - Epidermal growth factor receptor protects from immune privilege collapse and scarring hair follicle destruction
EGFR helps protect hair follicles from damage and scarring.
research Tofacitinib for the treatment of severe alopecia areata and variants: A retrospective cohort study of 90 patients
Tofacitinib is effective and safe for treating severe alopecia areata and related conditions.
research The role of 5-alpha-reductase inhibitors in active surveillance
5-alpha-reductase inhibitors might help slow down low-risk prostate cancer, but their use should be cautious.
research Moving Chemoprevention Forward into the Most Promising Areas of Study
Further research is needed to develop effective cancer prevention strategies.
research Molecular monitoring of short- and long-term transcriptional effects of hair growth stimulating agents
Hair growth serums A and C can affect hair growth genes and pathways, suggesting potential for personalized hair loss treatments.
research Insight into Recent Advances in Degrading Androgen Receptor for Castration-Resistant Prostate Cancer
New treatments targeting androgen receptors show promise for drug-resistant prostate cancer.
research A Case of Tofacitinib for the Treatment of Resistant Vitiligo and Sustained Repigmentation After Discontinuation
A woman's vitiligo improved with tofacitinib treatment, and her skin color remained even after stopping the medication, but there are concerns about cancer risk.
research Tofacitinib citrate alleviates alopecia universalis symptoms in recent case study
Tofacitinib helped a person with total body hair loss grow hair again without bad side effects.
research Comparison of the pharmacoeconomic profiles of treatment regimens for field pattern actinic keratoses
Some blood pressure medications are linked to a higher risk of skin cancer.
research BH17 Bridging the gap: identifying dual-targeting therapies for patients with alopecia areata and coexisting immune-mediated inflammatory diseases
Dual-targeting therapies like Janus kinase inhibitors may treat both alopecia areata and other immune diseases.
research 0950 Exploring hair aging through ex vivo induction of DNA damage and senescence
BrdU speeds up hair follicle aging and reduces hair quality.
research Baricitinib Provides Sustained, Long-Term Efficacy With Consistent Safety for Up to 5 Years of Treatment in Adults With Severe Alopecia Areata: Final Results From BRAVE-AA1 and BRAVE-AA2
Baricitinib is effective and safe for treating severe alopecia areata for up to 5 years.
research Data from Ribonucleotide Excision Repair Is Essential to Prevent Squamous Cell Carcinoma of the Skin
Ribonucleotide excision repair is crucial to prevent skin cancer.
research Decision letter: Interplay of opposing fate choices stalls oncogenic growth in murine skin epithelium
Skin cells can naturally limit the growth of cancerous changes by balancing cell renewal and differentiation.
research Correction: RASopathic Skin Eruptions during Vemurafenib Therapy
Vemurafenib causes significant skin side effects, requiring regular dermatologist care and sun protection.
research 201 Analysis of mice skin distribution using MALDI-MSI after subcutaneous injections of a new potent novel inhibitor of human hair growth, FOL-005
Some men don't respond to common hair loss treatments, but a new inhibitor, FOL-005, shows promise for targeting unwanted hair growth.
research Analysis of breast health outcomes in women on oral 5-alpha reductase inhibitors: A single-center retrospective cohort study
Oral 5-alpha reductase inhibitors do not increase breast cancer or benign breast disorder risk in women.
research Nilontinib induced keratosis pilaris atrophicans
Nilotinib can cause skin issues like red bumps and hair loss.
research A Randomized, Double-Blind, Placebo-Controlled Trial to Determine the Effectiveness of Botanically Derived Inhibitors of 5-α-Reductase in the Treatment of Androgenetic Alopecia
Natural 5AR inhibitors effectively improve mild to moderate hair loss in men.
research Analysis of Data From Breast Diseases Treated With 5-Alpha Reductase Inhibitors for Benign Prostatic Hyperplasia
Medicines for enlarged prostate may raise the risk of breast growth and tenderness but not breast cancer.
research Long-term use of 5α-reductase inhibitors and the risk of male breast cancer
Taking 5α-reductase inhibitors does not significantly increase the risk of breast cancer in men.